Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Journal of Biomechanics|March 16, 2010
On stiffness of scaffolds for bone tissue engineering-a numerical studyStefan Sturm, Shiwei Zhou, Yiu-Wing Mai, et al.Journal of Cardiovascular Pharmacology|November 25, 2011
No evidence of QT prolongation with supratherapeutic doses of aleglitazarStefan Sturm, Darren Bentley, Paul Jordan, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 18, 2010
An automated screening method for drugs and toxic compounds in human serum and urine using liquid chromatography-tandem mass spectrometryStefan Sturm, Felix Hammann, Juergen Drewe, et al.Clinical Therapeutics|January 17, 2012
Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteersStefan Sturm, Michael Seiberling, Idelette Weick, et al.Diabetes, Obesity & Metabolism|December 17, 2016
Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutideMylène Giraudon, Stefan Sturm, Nathalie Lambert, et al.International Journal of Pharmaceutics|July 29, 2017
Early pediatric formulation development with new chemical entities: Opportunities of e-tongue besides human taste assessmentLaura Isabell Immohr, Angela Dischinger, Peter Kühl, et al.Clinical Pharmacology and Therapeutics|January 21, 2020
Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and InfantsLeonid Gibiansky, Patanjali Ravva, Neil J Parrott, et al.British Journal of Clinical Pharmacology|November 3, 2017
Results and evaluation of a first-in-human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methodsStefan Sturm, Marie-Laure Delporte, Salah Hadi, et al.Clinical Pharmacokinetics|April 11, 2019
Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I TrialsKatrijn Bogman, Jochen Brumm, Carsten Hofmann, et al.Open Forum Infectious Diseases|October 30, 2019
Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With InfluenzaFrancisco Bautista, Dan Engelhard, Carmelo Rizzari, et al.Pageof 2